Numerous studies have indicated that the transcription of GCLC is controlled by nuclear factor erythroid 2-related factor 2 signaling [37, 41, 42], and that it correlates with prognosis in various cancers [43, 44]. This evidence concerns the gene NFE2L2 and cancer.